News | Balloon Catheter | April 04, 2024

FDA Announces Medos International Sàrl Recall of Cerenovus CEREBASE DA Guide Sheath due to Cracking of the Distal Catheter Shaft

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. 

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling Cerenovus CEREBASE DA Guide Sheath due to a crack found in the far end of the catheter, where different parts of the catheter are joined together.

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.

Recalled Product 

  • Product Names: 
    • CERENOVUS CEREBASE DA Guide Sheath, Part Numbers:  
      • GS9070SD;
      • GS9080SD;  
      • GS9090SD;  
      • GS9095SD; 
    • Neurovascular guide catheter, single-use 
  • Product Codes: QJP 
  • Manufacturing Dates: July 7, 2023, and later
  • Distribution Dates: June 14, 2023, to December 14, 2023 
  • Devices Recalled in the U.S.: 1,343
  • Date Initiated by Firm: February 2, 2024 

Device Use 

The CEREBASE DA Guide Sheath is a neurovascular catheter. This type of catheter is commonly used in procedures where precise navigation and access to blood vessels in the brain are required. This catheter is designed to help deliver interventional devices into the blood vessels in the brain, allowing doctors to place devices like stents or coils, to treat neurovascular diseases and conditions. 

Reason for Recall

Medos International Sàrl is recalling the Cerenovus CEREBASE DA Guide Sheath due to complaints describing fractures of the distal catheter shaft. This is a crack found in the far end of the catheter that is placed in the vessels in the brain, where different parts of the catheter are joined together.

The use of the affected product may result in surgical procedural delay, vascular injury or hemorrhage, and in extreme rare occasions it may result in embolism.  
There have been 3 reported injuries.

There have been no reports of death.

Who May be Affected

  • Healthcare professionals who use the CEREBASE DA Guide Sheath in vascular procedures such as surgeries on the brain. 
  • People who are having procedures where precise navigation and access to blood vessels in the brain are required.

What to Do 

On February 2, 2024, Johnson & Johnson MedTech, on behalf of Medos, sent all affected customers an Urgent Medical Device Recall. 

The letter requested customers to: 

  • Examine inventory and quarantine any product subject to this recall.
  • Remove any product subject to this recall and communicate the issue to anyone who needs to be informed.
  • Contact any facility where affected products may have been forwarded to arrange their return.
  • Complete the Business Reply Form (BRF) confirming receipt of the notice and scan and email signed form to [email protected] or fax it to (305) 265-6889.
    • Attention Line: Cerebase FA2350411
  • Follow instructions in the letter and immediately call 1-844-483-3882 to return any inventory of CEREBASE DA Guide Sheath devices subject to the recall. To receive credit reimbursement, customers must return product subject to the recall.
    • Attention Line: Cerebase FA2350411

Contact Information  

Customers in the U.S. with questions about this recall should contact Medos at [email protected] 

Additional Resources  

How do I report a problem? 

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program using an online form, regular mail, or FAX. 


Related Content

News | FDA

Dec.1, 2025 – MannKind Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA ...

Home December 01, 2025
Home
News | FDA

Nov. 18, 2025 — RapidAI announced U.S. Food and Drug Administration (FDA) clearance of Aortic Management, part of the ...

Home November 18, 2025
Home
News | FDA

Nov. 11, 2025 -— Integra LifeSciences Holdings Corp. has announced the FDA 510(k) clearance for use of its CUSA Clarity ...

Home November 18, 2025
Home
News | FDA

Nov. 10, 2025 — Stereotaxis has received U.S. Food and Drug Administration 510(k) clearance for its latest generation ...

Home November 11, 2025
Home
News | FDA

Oct. 29, 2025 — Circle Cardiovascular Imaging Inc., a provider of cardiovascular imaging solutions, recently announced ...

Home November 03, 2025
Home
News | FDA

Oct. 24, 2025 —YorLabs, Inc., a medical technology company developing next-generation intracardiac imaging solutions for ...

Home October 27, 2025
Home
News | FDA

Oct. 16, 2025 — Thirona recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance ...

Home October 16, 2025
Home
News | FDA

Oct. 14, 2025 — Nurea has announced that its PRAEVAorta 2 software has received FDA 510(k) clearance, enabling entry ...

Home October 14, 2025
Home
News | FDA

July 7, 2025 — Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) approval to expand the ...

Home July 08, 2025
Home
News | FDA

June 12, 2025 — Viz.ai recently announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for ...

Home June 12, 2025
Home
Subscribe Now